Year: 2022

Tinlarebant (a/k/a LBS-008) is Belite Bio’s orally administered tablet intended as an early intervention to slow disease progression in patients affected with Stargardt Disease (STGD1) and Dry Age-related Macular Degeneration (Dry AMD) There are currently no approved treatments for STGD1 and Dry AMD Currently, a 2-year Phase 2 study in adolescent STGD1 patients is ongoing and a global Phase 3 study in adolescent STGD1 patients (the “DRAGON” study) is recruiting subjects 12-month interim data from the ongoing Phase 2 STGD1 study continues to show halting or slowing of lesion growth Tinlarebant has been granted Fast Track Designation and Rare Pediatric Disease Designation in the U.S., and Orphan Drug Designation in both the U.S. and Europe for STGD1SAN DIEGO, Nov. 18, 2022 (GLOBE NEWSWIRE) — Belite Bio, Inc (NASDAQ: BLTE), a San...

FORT WORTH, Texas, Nov. 18, 2022 (GLOBE NEWSWIRE) — TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that it has priced a $10.675 million underwritten offering of 9,282,609 shares of its common stock and warrants to purchase up to 4,641,305 shares of common stock. The warrants are being sold at the rate of one warrant for every two shares of common stock. The public offering price, before the underwriters’ discount and commissions, for each share of common stock and accompanying warrant is $1.15. All of the securities in the offering were sold by the TFF Pharmaceuticals, Inc. In addition, the Company has granted the underwriters a 45-day option...

TORONTO, Nov. 18, 2022 (GLOBE NEWSWIRE) — VVC Exploration Corporation, dba VVC Resources, (“VVC” or the “Company“) announces the following: Warrant Exercises From October 1 to November 17, 2022, the Company received gross proceeds of $1.5 million pursuant to the exercise of Series AE and AA warrants. Shareholders holding Series AA warrants are reminded that these warrants expire on November 30, 2022. Stockhouse Publishing Pursuant to an arrangement with Stockhouse Publishing Ltd. in 2021, VVC is settling $15,000 of indebtedness by the issuance of 214,285 shares at the price of $0.07. The Securities to be issued pursuant to this transaction will be subject to the approval of the TSX Venture Exchange and to the applicable statutory, exchange and regulatory hold period of four months and any other required...

The Event Technology Awards are celebrating their tenth anniversary and recognise the achievements of companies delivering digital and technological solutions to the events industry. VANCOUVER, B.C., Nov. 18, 2022 (GLOBE NEWSWIRE) — Fobi AI Inc. (FOBI: TSXV FOBIF: OTCQB) (the “Company” or “FOBI”), a leader in providing real-time data analytics through artificial intelligence to drive operational efficiencies and profitability, is pleased to announce that their digital ticketing solution CheckPoint has won the award for best Ticketing Technology at the 2022 Event Technology Awards. The Event Technology Awards, which are now running for their tenth year, recognise the achievements of companies delivering digital and technological solutions to the events industry. They are very coveted and well-renowned awards that have been won by...

TORONTO, Nov. 18, 2022 (GLOBE NEWSWIRE) — Shawcor Ltd. (“Shawcor” or the “Company”) (TSX: SCL) announced that it has sold its Oilfield Asset Management (“OAM”) operating unit to Force Inspection Services Inc. (“Force”), in a transaction generating at least C$15 million in gross proceeds. Shawcor will retain OAM related Western Canadian real-estate assets which it may elect to sell at a future date. As part of the transaction, Shawcor has agreed to lease these properties to Force. The OAM business, reported within the Company’s Composite Systems (“CS”) segment, is a provider of downhole tubular inspection, repair and inventory management services to the Western Canadian energy market. It generated revenue of approximately C$38.1 million with an adjusted EBITDA of approximately C$5.3 million in the first nine months of 2022. Proceeds...

BBS-Bioactive Bone Substitutes Oyj, Company release, 18 November 2022 at 2.30 p.m. EET BBS-Bioactive Bone Substitutes Oyj (BBS) organized a rights issue from May 18 to June 3, 2022. In connection with the share issue, a total of 670,962 warrants from two different series (TO1 and TO2) were also granted to the subscribers. Each warrant gives its owner the right to subscribe for one new share at a discounted price. Information about the first series of warrants (TO1):Subscription period: For the first warrant series (TO1), the subscription period starts on Monday 21 November 2022 and ends on Friday 2 December 2022. Place of subscription: The subscription place in Finland is the account and asset managers and in Sweden Hagberg & Aneborn Fondkomission AB. The subscription order must be given in accordance with the instructions given...

BBS-Bioactive Bone Substitutes Oyj, Company release, Inside Information, 18 November 2022 at 2.30 p.m. EET The Notified Body has completed its first audit (15-18 November 2022) and has delivered its audit report to the company. The audit was focused on the quality system of BBS-Bioactive Bone Substitutes Oyj (BBS), and it was a part of the CE marking process of the company’s first product (ARTEBONE® Paste bone filler). During the authorities’ first audit, the Notified Body inspected documentation related to the quality system. No critical non-conformities related to the quality system were reported during the audit and the CE marking approval process may thus proceed as planned. “We are very pleased with the results of the audit. We have been successful in developing our quality system further, as the audit revealed only minor non-conformities,...